CA2816288C - Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative - Google Patents

Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative Download PDF

Info

Publication number
CA2816288C
CA2816288C CA2816288A CA2816288A CA2816288C CA 2816288 C CA2816288 C CA 2816288C CA 2816288 A CA2816288 A CA 2816288A CA 2816288 A CA2816288 A CA 2816288A CA 2816288 C CA2816288 C CA 2816288C
Authority
CA
Canada
Prior art keywords
plga
acid
rotigotine
microspheres
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2816288A
Other languages
English (en)
French (fr)
Other versions
CA2816288A1 (en
Inventor
Youxin Li
Aiping Wang
Wanhui Liu
Kaoxiang Sun
Jun Li
Lifang Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneora Pharma Shijiazhuang Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of CA2816288A1 publication Critical patent/CA2816288A1/en
Application granted granted Critical
Publication of CA2816288C publication Critical patent/CA2816288C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2816288A 2010-11-25 2011-11-25 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative Active CA2816288C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010576447 2010-11-25
CN201010576447.5 2010-11-25
PCT/CN2011/001958 WO2012068783A1 (en) 2010-11-25 2011-11-25 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

Publications (2)

Publication Number Publication Date
CA2816288A1 CA2816288A1 (en) 2012-05-31
CA2816288C true CA2816288C (en) 2016-01-26

Family

ID=46145374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816288A Active CA2816288C (en) 2010-11-25 2011-11-25 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

Country Status (14)

Country Link
US (1) US9265835B2 (https=)
EP (1) EP2642993B1 (https=)
JP (2) JP6006225B2 (https=)
KR (1) KR101481643B1 (https=)
CN (1) CN103458895B (https=)
AU (1) AU2011334494B2 (https=)
BR (1) BR112013012726B1 (https=)
CA (1) CA2816288C (https=)
ES (1) ES2572948T3 (https=)
MY (1) MY165003A (https=)
PH (1) PH12013500923A1 (https=)
PL (1) PL2642993T3 (https=)
RU (1) RU2589700C2 (https=)
WO (1) WO2012068783A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8682462B2 (en) 2011-08-13 2014-03-25 Colin M. Leonard Systems and methods for dynamic audio processing
US11074031B1 (en) 2016-09-06 2021-07-27 Colin Leonard Systems and methods for dynamic audio processing
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
CA2935311C (en) 2013-12-31 2018-11-27 Pb&B Sa Controlled release fatty acid compositions for use in body reconstruction and body-shaping
CN105310974B (zh) * 2014-08-01 2019-08-23 山东绿叶制药有限公司 罗替戈汀及其衍生物或其药用盐的植入剂
CN106474070B (zh) * 2015-08-26 2020-03-17 四川科伦药物研究院有限公司 一种克服停滞期、恒速释放疏水性药物的微球及制备方法
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
ES2855976T3 (es) * 2016-07-21 2021-09-27 Shandong luye pharmaceutical co ltd Behenato de rotigotina y procedimiento de fabricación y aplicación del mismo
WO2018045000A1 (en) 2016-08-30 2018-03-08 Dow Agrosciences Llc Picolinamides as fungicides
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
EP4104820A4 (en) * 2020-02-14 2024-04-17 G2GBIO, Inc. Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
WO2025243901A1 (ja) * 2024-05-21 2025-11-27 株式会社 SENTAN Pharma 注射製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
JP4927729B2 (ja) 2004-07-16 2012-05-09 オークウッド ラボラトリーズ，エル．エル．シー． 性腺刺激ホルモン放出ホルモンアンタゴニスト
CN1762495B (zh) 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
KR20070059161A (ko) 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
JP5222550B2 (ja) 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法

Also Published As

Publication number Publication date
AU2011334494B2 (en) 2015-11-05
CN103458895B (zh) 2014-07-09
PH12013500923A1 (en) 2016-02-08
WO2012068783A1 (en) 2012-05-31
JP6067803B2 (ja) 2017-01-25
EP2642993A4 (en) 2014-05-14
RU2589700C2 (ru) 2016-07-10
RU2013128430A (ru) 2014-12-27
JP6006225B2 (ja) 2016-10-12
US20130309314A1 (en) 2013-11-21
US9265835B2 (en) 2016-02-23
KR101481643B1 (ko) 2015-01-12
PL2642993T3 (pl) 2016-09-30
JP2013543874A (ja) 2013-12-09
BR112013012726B1 (pt) 2022-03-29
CN103458895A (zh) 2013-12-18
CA2816288A1 (en) 2012-05-31
EP2642993A1 (en) 2013-10-02
MY165003A (en) 2018-02-28
KR20130130727A (ko) 2013-12-02
HK1186978A1 (en) 2014-03-28
AU2011334494A1 (en) 2013-07-11
ES2572948T3 (es) 2016-06-03
JP2016028043A (ja) 2016-02-25
US20140377369A2 (en) 2014-12-25
BR112013012726A2 (https=) 2017-04-04
EP2642993B1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
CA2816288C (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
EP3125871B1 (en) Preparation of peptide loaded plga microspheres with controlled release characteristics
US8586092B2 (en) Fulvestrant nanosphere/microsphere and preparative method and use thereof
EP2832349B1 (en) Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
CN102316867A (zh) 氨氯地平微球制剂、其制备方法及应用
CN118477048B (zh) 一种布瑞哌唑缓释微球及其制备方法
ES2975989T3 (es) Composiciones de micropartículas inyectables de naltrexona de acción prolongada
Wang et al. Modification of three-phase drug release mode of octreotide PLGA microspheres by microsphere-gel composite system
US20180177777A1 (en) Formulations for mitigating opioid overdose and methods of making and using the same
EP4454636A1 (en) Continuous delivery preparation capable of being stably released and preparation method therefor
CN102784111A (zh) 一种多巴胺受体激动剂类药物的缓释制剂
CN109419771B (zh) 十一酸睾酮缓释药物组合物、其制备方法及用途
HK1186978B (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
Roy et al. Effect formulation variables on physicochemical characteristics and drug release potential of oral glipizide microspheres
Bota PLGA in situ forming microparticles loaded with nanosized dexamethasone as long-term drug delivery carriers
JP2025511372A (ja) 新規組成物
Chen et al. Dichloromethane evaporative behavior during the solidifying process of ovalbumin-loaded poly (DL lactic-co-glycolic acid) microparticles
CN115006354A (zh) 一种利培酮-共混plga缓释微球及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140109

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241021

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241021